Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Clinical trial NCT05477563 · RECRUITING

Trial details

NCT number: NCT05477563
Sponsor: Vertex Pharmaceuticals Incorporated
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Beta-Thalassemia Thalassemia Hematologic Diseases Genetic Diseases, Inborn Hemoglobinopathies Sickle Cell Disease Sickle Cell Anemia

Start date: 2022-08-02
Primary completion: 2027-06-09
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.